Market Summary
USD162.88-5.70
Delayedas of 21 Sep 2023, 11:40 am-3.38%
RGEN Stock Price
RGEN RSI Chart
RGEN Valuation
RGEN Price/Sales (Trailing)
RGEN Profitability
RGEN Fundamentals
RGEN Revenue
RGEN Earnings
Price Action
52 Week Range
134.64225.62
(Low)(High)
Last 7 days
6.1%
Last 30 days
4.7%
Last 90 days
12.5%
Trailing 12 Months
-21.5%
RGEN Financial Health
RGEN Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for RGEN
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-29 | DAWES KAREN A | acquired | 133,943 | 18.12 | 7,392 | - |
2023-08-29 | DAWES KAREN A | sold | -145,673 | 171 | -850 | - |
2023-05-18 | BARTHELEMY NICOLAS | acquired | - | - | 686 | - |
2023-05-18 | DAWES KAREN A | acquired | - | - | 798 | - |
2023-05-18 | Mhatre Rohin | acquired | - | - | 686 | - |
2023-05-18 | Konstantinov Konstantin | acquired | - | - | 686 | - |
2023-05-18 | Madaus Martin D | acquired | - | - | 686 | - |
2023-05-18 | EGLINTON MANNER CARRIE | acquired | - | - | 686 | - |
2023-05-18 | MUIR GLENN P | acquired | - | - | 686 | - |
2023-05-16 | Snodgres Jon | sold (taxes) | -109,361 | 154 | -710 | chief financial officer |
Which funds bought or sold RGEN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | added | 300 | 398 | 566 | -% |
2023-08-25 | Yarbrough Capital, LLC | unchanged | - | -65,851 | 346,294 | 0.02% |
2023-08-24 | Alberta Investment Management Corp | unchanged | - | -1,730,560 | 9,100,550 | 0.09% |
2023-08-22 | COMERICA BANK | new | - | 6,000 | 6,000 | -% |
2023-08-22 | COMERICA BANK | new | - | 17,980,000 | 17,980,000 | 1.88% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 12.28 | -114,821 | 1,930,070 | -% |
2023-08-21 | BOKF, NA | reduced | -32.67 | -18,351 | 23,907 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | unchanged | - | -222 | 1,311 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 10.25 | -102,000 | 1,291,000 | 0.01% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -3.14 | -2,774,980 | 12,128,900 | 0.02% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Repligen
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 15, 2023 | eddleman roy t | 4.87% | 2,705,689 | SC 13G/A | |
| Feb 14, 2023 | price t rowe associates inc /md/ | 9.1% | 5,070,657 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.37% | 5,205,155 | SC 13G/A | |
| Jan 23, 2023 | blackrock inc. | 11.0% | 6,123,594 | SC 13G/A | |
| Sep 08, 2022 | blackrock inc. | 10.2% | 5,686,997 | SC 13G | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 5.5% | 3,042,655 | SC 13G | |
| Feb 10, 2022 | vanguard group inc | 8.89% | 4,912,769 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 9.4% | 5,189,189 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 8.12% | 4,410,742 | SC 13G/A | |
| Feb 05, 2021 | eddleman roy t | 6.65% | 3,500,000 | SC 13G/A |
Recent SEC filings of Repligen
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 12, 2023 | 8-K | Current Report | |
| Aug 30, 2023 | 4 | Insider Trading | |
| Aug 29, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 02, 2023 | 8-K | Current Report | |
| Aug 02, 2023 | 10-Q | Quarterly Report |
RGEN Fair Value
Loading...
Peers (Alternatives to Repligen)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
A | 33.0B | 7.0B | -5.38% | -12.23% | 29.09 | 4.71 | 5.03% | -14.68% |
MTD | 24.7B | 4.0B | -3.30% | -3.12% | 27.83 | 6.25 | 2.30% | 16.37% |
ILMN | 21.9B | 4.5B | -17.36% | -28.94% | -5.22 | 4.9 | -4.92% | -21931.58% |
TECH | 11.2B | 1.1B | -9.93% | -5.35% | 39.16 | 9.83 | 2.81% | 4.86% |
| MID-CAP | ||||||||
RGEN | 9.4B | 134.2M | 4.73% | -21.54% | 68.08 | 70.03 | -82.77% | -13.43% |
| SMALL-CAP | ||||||||
PACB | 2.4B | 146.1M | -8.89% | 61.75% | -7.4 | 16.16 | 4.72% | -55.19% |
QTRX | 960.9M | 112.0M | 5.18% | 169.83% | -14.6 | 8.58 | 0.83% | 16.42% |
ADPT | 749.3M | 189.6M | -19.57% | -31.57% | -3.92 | 3.95 | 18.74% | 17.75% |
HBIO | 175.0M | 114.1M | -1.44% | 44.37% | -32.24 | 1.53 | -5.49% | -48.58% |
CDXS | 118.7M | 99.2M | -1.73% | -74.89% | -2.09 | 1.2 | -26.56% | -199.52% |
CDXC | 103.3M | 80.9M | -10.97% | -2.13% | -15.91 | 1.28 | 17.20% | 77.07% |
BNGO | 99.7M | 31.5M | -1.32% | 40.85% | -0.68 | 3.16 | 35.12% | -38.47% |
NSTG | 73.7M | 143.9M | -41.73% | -89.43% | -0.44 | 0.51 | 0.71% | -18.99% |
CSBR | 72.1M | 52.7M | -20.39% | -41.08% | -9.55 | 1.37 | 2.10% | -1984.29% |
Repligen News
Returns for RGEN
Cumulative Returns on RGEN
32.5%
10-Year Cumulative Returns
26.0%
7-Year Cumulative Returns
25%
5-Year Cumulative Returns
4.9%
3-Year Cumulative Returns
Risks for RGEN
What is the probability of a big loss on RGEN?
67.7%
Probability that Repligen stock will be more than 20% underwater in next one year
34.6%
Probability that Repligen stock will be more than 30% underwater in next one year.
22.3%
Probability that Repligen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does RGEN drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Repligen was unfortunately bought at previous high price.
Drawdowns
Financials for Repligen
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -26.5% | 134 | 183 | 206 | 801 | 779 | 734 | 671 | 593 | 509 | 433 | 366 | 327 | 302 | 286 | 270 | 253 | 233 | 210 | 194 | 184 | 171 |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 210 | 188 | 172 | 161 | 151 | 140 | 129 | 116 | 108 | 102 | 91.00 |
| Costs and Expenses | -0.8% | 577 | 582 | 577 | 588 | 573 | 543 | 503 | 445 | 386 | 339 | 296 | 269 | 257 | 249 | 234 | 215 | 195 | 179 | 168 | 162 | 158 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 296 | 269 | 257 | 249 | 234 | 215 | 195 | 179 | 168 | 162 | 158 |
| S&GA Expenses | -2.6% | 212 | 218 | 216 | 215 | 209 | 199 | 184 | 168 | 149 | 131 | 120 | 112 | 107 | 104 | 96.00 | 85.00 | 76.00 | 69.00 | 66.00 | 64.00 | 64.00 |
| R&D Expenses | -1.7% | 43.00 | 44.00 | 44.00 | 42.00 | 41.00 | 39.00 | 34.00 | 32.00 | 27.00 | 23.00 | 20.00 | 19.00 | 20.00 | 21.00 | 19.00 | 17.00 | 16.00 | 16.00 | 16.00 | 16.00 | 14.00 |
| EBITDA | -100.0% | - | 252 | 271 | 252 | 248 | 220 | 205 | 169 | 144 | 123 | 98.00 | 86.00 | 69.00 | 60.00 | 56.00 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 1.38* | 1.31* | 0.31* | 0.30* | 0.30* | 0.31* | 0.29* | 0.28* | 0.28* | 0.27* | 0.26* | 0.23* | 0.21* | 0.21* | - | - | - | - | - | - |
| Interest Expenses | 0.3% | 1.00 | 1.00 | 1.00 | 4.00 | 6.00 | 9.00 | 11.00 | 10.00 | 10.00 | 11.00 | 11.00 | 12.00 | 12.00 | 11.00 | 9.00 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 |
| Earnings Before Taxes | -17.6% | 162 | 196 | 219 | 201 | 195 | 179 | 154 | 133 | 110 | 82.00 | 59.00 | 49.00 | 33.00 | 26.00 | 26.00 | 29.00 | 34.00 | 27.00 | 21.00 | 16.00 | 7.00 |
| EBT Margin | -100.0% | - | 1.07* | 1.06* | 0.25* | 0.25* | 0.24* | 0.23* | 0.23* | 0.22* | 0.19* | 0.16* | 0.15* | 0.11* | 0.09* | 0.10* | - | - | - | - | - | - |
| Net Income | -17.8% | 138 | 168 | 186 | 166 | 159 | 146 | 128 | 119 | 100 | 80.00 | 60.00 | 44.00 | 31.00 | 23.00 | 21.00 | 23.00 | 27.00 | 21.00 | 17.00 | 23.00 | 23.00 |
| Net Income Margin | -100.0% | - | 0.92* | 0.90* | 0.21* | 0.20* | 0.20* | 0.19* | 0.20* | 0.20* | 0.18* | 0.16* | 0.13* | 0.10* | 0.08* | 0.08* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 94.00 | 87.00 | 63.00 | 45.00 | 46.00 | 52.00 | 38.00 | 44.00 | 36.00 | 40.00 | 47.00 | 46.00 | 46.00 | 49.00 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 0.4% | 2,549 | 2,538 | 2,525 | 2,463 | 2,445 | 2,384 | 2,358 | 2,241 | 2,016 | 1,927 | 1,903 | 1,476 | 1,442 | 1,406 | 1,400 | 1,379 | 1,068 | 798 | 775 | 762 | 745 |
| Current Assets | -2.0% | 999 | 1,019 | 998 | 953 | 976 | 945 | 932 | 911 | 984 | 926 | 902 | 697 | 687 | 651 | 642 | 622 | 316 | 284 | 276 | 267 | 253 |
| Cash Equivalents | 16.8% | 604 | 517 | 523 | 573 | 597 | 585 | 604 | 621 | 734 | 711 | 717 | 553 | 560 | 539 | 537 | 522 | 218 | 196 | 194 | 190 | 176 |
| Inventory | -1.6% | 241 | 245 | 238 | 243 | 239 | 214 | 184 | 156 | 136 | 110 | 95.00 | 79.00 | 70.00 | 62.00 | 55.00 | 52.00 | 51.00 | 45.00 | 42.00 | 42.00 | 41.00 |
| Net PPE | 5.1% | 203 | 193 | 191 | 174 | 168 | 148 | 125 | 100 | 85.00 | 72.00 | 67.00 | 55.00 | 52.00 | 50.00 | 48.00 | 43.00 | 38.00 | 35.00 | 32.00 | 29.00 | 24.00 |
| Goodwill | 1.7% | 871 | 856 | 856 | 851 | 854 | 859 | 860 | 834 | 618 | 618 | 618 | 482 | 13.00 | 468 | 468 | 469 | 470 | 326 | 327 | 327 | 327 |
| Liabilities | -3.3% | 578 | 598 | 614 | 627 | 640 | 617 | 608 | 526 | 413 | 371 | 374 | 351 | 342 | 337 | 340 | 334 | 189 | 173 | 159 | - | - |
| Current Liabilities | -7.8% | 374 | 405 | 404 | 411 | 424 | 424 | 375 | 349 | 332 | 313 | 319 | 51.00 | 44.00 | 42.00 | 48.00 | 39.00 | 141 | 130 | 130 | 130 | 121 |
| Shareholder's Equity | 1.6% | 1,971 | 1,940 | 1,911 | 1,835 | 1,805 | 1,766 | 1,750 | 1,715 | 1,603 | 1,556 | 1,529 | 1,125 | 1,100 | 1,070 | 1,060 | 1,045 | 879 | 625 | 616 | 606 | 599 |
| Retained Earnings | 4.7% | 446 | 426 | 397 | 349 | 308 | 258 | 17.00 | 165 | 131 | 95.00 | 66.00 | 46.00 | 32.00 | 16.00 | 6.00 | 2.00 | 1.00 | -7.51 | -0.68 | -21.21 | -26.00 |
| Additional Paid-In Capital | 1.1% | 1,561 | 1,545 | 1,547 | 1,541 | 1,534 | 1,529 | 1,572 | 1,560 | 1,475 | 1,468 | 1,461 | 1,088 | 1,082 | 1,074 | 1,068 | 1,064 | 893 | 646 | 643 | 639 | 635 |
| Shares Outstanding | 0.2% | 56.00 | 56.00 | 56.00 | 56.00 | 55.00 | 55.00 | 55.00 | 55.00 | 55.00 | 55.00 | 55.00 | 53.00 | 52.00 | 52.00 | 52.00 | 51.00 | 46.00 | 44.00 | 44.00 | 44.00 | 44.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -7.0% | 149 | 160 | 172 | 160 | 141 | 133 | 119 | 84.00 | 83.00 | 62.00 | 63.00 | 65.00 | 66.00 | 67.00 | 67.00 | 55.00 | 53.00 | 41.00 | 33.00 | 42.00 | 21.00 |
| Share Based Compensation | -5.6% | 25.00 | 27.00 | 27.00 | 28.00 | 29.00 | 29.00 | 28.00 | 25.00 | 22.00 | 19.00 | 17.00 | 16.00 | 15.00 | 14.00 | 13.00 | 12.00 | 12.00 | 11.00 | 10.00 | 10.00 | 9.00 |
| Cashflow From Investing | 42.5% | -123 | -214 | -233 | -174 | -249 | -240 | -221 | -317 | -218 | -205 | -201 | -50.21 | -23.52 | -206 | -205 | -203 | -200 | -16.30 | -14.04 | -10.20 | -117 |
| Cashflow From Financing | -60.0% | -17.41 | -10.88 | -13.34 | -12.83 | -14.20 | -11.57 | 1.00 | 300 | 301 | 305 | 306 | 7.00 | 300 | 486 | 485 | 486 | 192 | 3.00 | 3.00 | 3.00 | 132 |
RGEN Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue: | ||||
| Revenue | $ 159,169 | $ 207,633 | $ 341,829 | $ 414,033 |
| Costs and operating expenses: | ||||
| Cost of product revenue | 79,307 | 86,260 | 161,152 | 168,616 |
| Research and development | 9,706 | 10,440 | 21,860 | 22,595 |
| Selling, general and administrative | 48,966 | 54,649 | 105,136 | 108,949 |
| Contingent consideration | 1,791 | (6,884) | 3,026 | (9,295) |
| Total costs and operating expenses | 139,770 | 144,465 | 291,174 | 290,865 |
| Income from operations | 19,399 | 63,168 | 50,655 | 123,168 |
| Other income (expenses): | ||||
| Investment income | 5,964 | 708 | 11,450 | 785 |
| Interest expense | (274) | (271) | (544) | (563) |
| Amortization of debt issuance costs | (457) | (453) | (914) | (905) |
| Other expenses | 528 | (3,396) | 605 | (3,798) |
| Other income (expenses), net | 5,761 | (3,412) | 10,597 | (4,481) |
| Income before income taxes | 25,160 | 59,756 | 61,252 | 118,687 |
| Income tax provision | 5,096 | 9,895 | 12,359 | 21,862 |
| Net income | $ 20,064 | $ 49,861 | $ 48,893 | $ 96,825 |
| Earnings per share: | ||||
| Basic | $ 0.36 | $ 0.9 | $ 0.88 | $ 1.75 |
| Diluted (Note 11) | $ 0.35 | $ 0.88 | $ 0.86 | $ 1.68 |
| Weighted average common shares outstanding: | ||||
| Basic | 55,705 | 55,444 | 55,648 | 55,399 |
| Diluted (Note 11) | 56,858 | 56,721 | 56,932 | 57,842 |
| Net Income (Loss) | $ 20,064 | $ 49,861 | $ 48,893 | $ 96,825 |
| Other comprehensive income (loss): | ||||
| Foreign currency translation adjustment | (6,068) | (15,517) | (2,795) | (20,205) |
| Comprehensive income | 13,996 | 34,344 | 46,098 | 76,620 |
| Products | ||||
| Revenue: | ||||
| Revenue | 159,133 | 207,597 | 341,754 | 413,960 |
| Royalty and other revenue | ||||
| Revenue: | ||||
| Revenue | $ 36 | $ 36 | $ 75 | $ 73 |
RGEN Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 603,656 | $ 523,458 |
| Marketable securities held to maturity | 0 | 100,299 |
| Accounts receivable, net of reserves of $1,571 and $1,365 at June 30, 2023 and December 31, 2022, respectively | 120,304 | 116,247 |
| Inventories, net | 240,869 | 238,277 |
| Prepaid expenses and other current assets | 33,754 | 19,837 |
| Total current assets | 998,583 | 998,118 |
| Property, plant and equipment, net | 202,564 | 190,673 |
| Intangible assets, net | 351,704 | 353,676 |
| Goodwill | 870,688 | 855,513 |
| Deferred tax assets | 1,756 | 840 |
| Operating lease right of use assets | 122,044 | 125,023 |
| Other noncurrent assets | 1,664 | 815 |
| Total noncurrent assets | 1,550,420 | 1,526,540 |
| Total assets | 2,549,003 | 2,524,658 |
| Current liabilities: | ||
| Accounts payable | 23,787 | 27,554 |
| Operating lease liability | 2,889 | 6,957 |
| Current contingent consideration | 16,363 | 13,950 |
| Accrued liabilities | 45,023 | 71,120 |
| Convertible Senior Notes, net | 285,521 | 284,615 |
| Total current liabilities | 373,583 | 404,196 |
| Deferred tax liabilities | 21,897 | 23,000 |
| Noncurrent operating lease liability | 134,438 | 131,389 |
| Noncurrent contingent consideration | 44,277 | 51,559 |
| Other noncurrent liabilities | 3,882 | 3,814 |
| Total noncurrent liabilities | 204,494 | 209,762 |
| Total liabilities | 578,077 | 613,958 |
| Commitments and contingencies (Note 8) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding | 0 | 0 |
| Common stock, $0.01 par value; 80,000,000 shares authorized; 55,744,896 shares at June 30, 2023 and 55,557,698 shares at December 31, 2022 issued and outstanding | 557 | 556 |
| Additional paid-in capital | 1,561,393 | 1,547,266 |
| Accumulated other comprehensive loss | (37,189) | (34,394) |
| Accumulated earnings | 446,165 | 397,272 |
| Total stockholders' equity | 1,970,926 | 1,910,700 |
| Total liabilities and stockholders' equity | $ 2,549,003 | $ 2,524,658 |
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.